FLT3 and acute myeloid leukemia: In this study, we tested the effect of LY3009120 on AML cells harboring mutant RAS or FLT3. We then explored whether LY3009120 has the potential to overcome bone marrow stroma-induced chemoresistance and examined its activity in combination with sorafenib.